TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Employees - 2, CEO - Dr. Mitchell Glass M.D., Sector - Healthcare, Country - US, Market Cap - 2.54M

Altman ZScore(max is 10): -9.16, Piotroski Score(max is 10): 2, Working Capital: $2710626, Total Assets: $21421084, Retained Earnings: $-129138286, EBIT: -6799145, Total Liabilities: $6701340, Revenue: $0

AryaFin Target Price - $0.06 - Current Price $0.18 - Analyst Target Price $32.00